-+ 0.00%
-+ 0.00%
-+ 0.00%

Design Therapeutics Q1 net loss narrows to $17.6 million; R&D expenses fall to $14.4 million

PUBT·04/28/2026 20:02:43
Listen to the news
Design Therapeutics Q1 net loss narrows to $17.6 million; R&D expenses fall to $14.4 million
  • Design Therapeutics posted a net loss of USD 17.6 million for the quarter ended March 31, 2026, with loss per share of USD 0.29.
  • Operating loss totaled USD 19.7 million, while R&D expenses eased to USD 14.4 million.
  • Cash, cash equivalents and investment securities rose to USD 222.8 million as of March 31.
  • RESTORE-FA Phase 1/2 multiple ascending dose trial of DT-216P2 continued dosing Friedreich ataxia patients, with an update on frataxin levels expected in the second half of 2026.
  • Design expects cash runway to fund planned operations into 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Design Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604281601PRIMZONEFULLFEED9708806) on April 28, 2026, and is solely responsible for the information contained therein.